ADC Therapeutics SA (ADCT)
NYSE: ADCT · IEX Real-Time Price · USD
3.480
-0.200 (-5.43%)
At close: Jul 2, 2024, 4:00 PM
3.460
-0.020 (-0.57%)
After-hours: Jul 2, 2024, 7:24 PM EDT
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 7.00, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 101.15% from the current stock price of 3.48.
Analyst Consensus: Buy
* Price targets were last updated on May 7, 2024.
Analyst Ratings
The average analyst rating for ADCT stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 4 | 3 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | May 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +129.89% | May 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +158.62% | Apr 15, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +216.09% | Mar 28, 2024 |
Financial Forecast
Revenue This Year
79.37M
from 69.56M
Increased by 14.11%
Revenue Next Year
92.35M
from 79.37M
Increased by 16.34%
EPS This Year
-1.93
from -2.94
EPS Next Year
-1.61
from -1.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 84.0M | 102.2M | 157.3M | 241.3M | 396.3M |
| Avg | 79.4M | 92.3M | 121.8M | 197.0M | 306.0M |
| Low | 74.0M | 78.6M | 80.3M | 145.3M | 261.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20.8% | 28.8% | 70.4% | 98.2% | 101.2% |
| Avg | 14.1% | 16.3% | 31.8% | 61.8% | 55.3% |
| Low | 6.4% | -1.0% | -13.1% | 19.4% | 32.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.62 | -1.13 | -0.80 |
| Avg | -1.93 | -1.61 | -1.39 |
| Low | -2.12 | -1.90 | -1.68 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.